All the news Showing 10 of 20 articles from: EASL 2014Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment in liver transplanted Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease Liz Highleyman / 17 April 2014 Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ... Interferon-free regimens BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks Caspar Thomson / 17 April 2014 A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon ... Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients Liz Highleyman / 16 April 2014 A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including ... Treatment guidelines European liver specialists recommend use of newest hepatitis C drugs Keith Alcorn / 12 April 2014 The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ... Transmission and prevention Treatment for prevention for hepatitis C in French drug users could cut HCV prevalence by two-thirds in 10 years Keith Alcorn / 12 April 2014 A combination of increased testing, improved linkage to care and treatment immediately after diagnosis with interferon-free regimens has the potential to substantially reduce the incidence and prevalence of hepatitis C virus ... Interferon-free regimens Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients Liz Highleyman / 11 April 2014 A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and people who were not cured ... Treatment for people living with HIV and HCV Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection Liz Highleyman / 11 April 2014 Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus ... Triple therapy 88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy Keith Alcorn / 11 April 2014 Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) ... AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections Keith Alcorn / 11 April 2014 A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the JW Goethe University Hospital, Frankfurt, ... Treatment guidelines WHO recommends global use of newest hepatitis C drugs, urges price reductions Keith Alcorn / 09 April 2014 The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for genotypes 1, 2, 3 and 4 or ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive